Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 277 articles:
HTML format



Single Articles


    October 2024
  1. FUCHAO C, Jingyue S, Xiao W
    Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy.
    J Clin Oncol. 2024 Oct 4:JCO2401571. doi: 10.1200/JCO-24-01571.
    PubMed    


  2. AL-SHAMSI HO, Abdelwahed N, Mokbel K
    Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double Standard?
    J Clin Oncol. 2024 Oct 3:JCO2401186. doi: 10.1200/JCO.24.01186.
    PubMed    


  3. PHILLIPS KA, Kotsopoulos J, Domchek SM, Terry MB, et al
    Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.
    J Clin Oncol. 2024 Oct 2:JCO2400176. doi: 10.1200/JCO.24.00176.
    PubMed     Abstract available


    September 2024
  4. BICKELL NA, Nattinger AB, McGinley EL, Schymura MJ, et al
    The Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery.
    J Clin Oncol. 2024 Sep 30:JCO2302638. doi: 10.1200/JCO.23.02638.
    PubMed     Abstract available


  5. YANG S
    Methodological Considerations for Ensuring Robustness in Exercise and Breast Cancer Recurrence Studies.
    J Clin Oncol. 2024 Sep 20:JCO2401299. doi: 10.1200/JCO-24-01299.
    PubMed    


  6. WARREN LEG, Bellon JR
    Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
    J Clin Oncol. 2024;42:3167-3169.
    PubMed    


  7. HAHN E, Sutradhar R, Paszat L, Nguyen L, et al
    Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.
    J Clin Oncol. 2024;42:3196-3206.
    PubMed     Abstract available


  8. HO AY, Shiao S, Kobald SA, Chen J, et al
    PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2024 Sep 19:JCO2400003. doi: 10.1200/JCO.24.00003.
    PubMed     Abstract available


  9. BHARDWAJ PV, Abdou Y
    Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies.
    J Clin Oncol. 2024 Sep 18:JCO2401295. doi: 10.1200/JCO-24-01295.
    PubMed     Abstract available


  10. TORRES JM, Sodipo MO, Hopkins MF, Chandler PD, et al
    Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2024 Sep 17:JCO2302311. doi: 10.1200/JCO.23.02311.
    PubMed     Abstract available


  11. LIU S, Hu R
    Insights and Limitations of the Study on Temporary Interruption of Endocrine Therapy and Assisted Reproductive Technology Use in Breast Cancer Survivors.
    J Clin Oncol. 2024 Sep 16:JCO2401227. doi: 10.1200/JCO-24-01227.
    PubMed    


  12. WEN Z, Duan S, Liu H
    Advancing Fertility Preservation in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy: Societal and Psychological Implications.
    J Clin Oncol. 2024 Sep 16:JCO2401204. doi: 10.1200/JCO-24-01204.
    PubMed    


  13. BARDIA A, Jhaveri K, Im SA, Pernas S, et al
    Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
    J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920.
    PubMed     Abstract available


  14. LOIBL S, Jassem J, Sonnenblick A, Parlier D, et al
    Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
    J Clin Oncol. 2024 Sep 11:JCO2302505. doi: 10.1200/JCO.23.02505.
    PubMed     Abstract available


  15. KANG D, Cho J, Zhao D, Kim J, et al
    Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial.
    J Clin Oncol. 2024;42:3115-3122.
    PubMed     Abstract available


  16. JHAVERI KL, Lim E, Jeselsohn R, Ma CX, et al
    Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
    J Clin Oncol. 2024 Sep 6:JCO2302733. doi: 10.1200/JCO.23.02733.
    PubMed     Abstract available


  17. JHAVERI KL, Accordino MK, Bedard PL, Cervantes A, et al
    Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
    J Clin Oncol. 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110.
    PubMed     Abstract available


  18. CLASEN SC, Miller ME
    How We Monitor Cardiac Health in Breast Cancer Survivors.
    J Clin Oncol. 2024 Sep 3:JCO2400757. doi: 10.1200/JCO.24.00757.
    PubMed     Abstract available


    August 2024
  19. ZULEY ML, Bandos AI, Duffy SW, Logue D, et al
    Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival.
    J Clin Oncol. 2024 Aug 21:JCO2400285. doi: 10.1200/JCO.24.00285.
    PubMed     Abstract available


  20. BRUNNER C, Arvandi M, Marth C, Egle D, et al
    Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.
    J Clin Oncol. 2024 Aug 20:JCO2400171. doi: 10.1200/JCO.24.00171.
    PubMed     Abstract available


  21. DILAWARI A, Buturla J, Osgood C, Gao X, et al
    US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
    J Clin Oncol. 2024 Aug 19:JCO2400427. doi: 10.1200/JCO.24.00427.
    PubMed     Abstract available


  22. REEDER-HAYES KE, Jackson BE, Kuo TM, Baggett CD, et al
    Structural Racism and Treatment Delay Among Black and White Patients With Breast Cancer.
    J Clin Oncol. 2024 Aug 6:JCO2302483. doi: 10.1200/JCO.23.02483.
    PubMed     Abstract available


  23. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    PubMed     Abstract available


    July 2024
  24. PATEL BK, Carnahan MB, Northfelt D, Anderson K, et al
    Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
    J Clin Oncol. 2024 Jul 26:JCO2202819. doi: 10.1200/JCO.22.02819.
    PubMed     Abstract available


  25. KOK M, Gielen RJ, Adams S, Lennerz JK, et al
    Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.
    J Clin Oncol. 2024 Jul 22:JCO2400372. doi: 10.1200/JCO.24.00372.
    PubMed    


  26. MATIKAS A, Mobus V, Greil R, Andersson A, et al
    Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
    J Clin Oncol. 2024 Jul 17:JCO2400178. doi: 10.1200/JCO.24.00178.
    PubMed     Abstract available


  27. KATZ SJ, Abrahamse P, Furgal A, Hodan R, et al
    Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
    J Clin Oncol. 2024 Jul 15:JCO2400122. doi: 10.1200/JCO.24.00122.
    PubMed     Abstract available


  28. OKEYA A, Shimomura A, Kitagawa D, Shimizu C, et al
    Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
    J Clin Oncol. 2024 Jul 11:JCO2400992. doi: 10.1200/JCO.24.00992.
    PubMed    


  29. RAMCHAND SK, Ghasem-Zadeh A, Hoermann R, White S, et al
    Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial.
    J Clin Oncol. 2024 Jul 2:JCO2302309. doi: 10.1200/JCO.23.02309.
    PubMed     Abstract available


    June 2024
  30. TARANTINO P, Tayob N, Villacampa G, Dang C, et al
    Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
    J Clin Oncol. 2024 Jun 27:JCO2302170. doi: 10.1200/JCO.23.02170.
    PubMed     Abstract available


  31. SCHMIDT JA, Woolpert KM, Hjorth CF, Farkas DK, et al
    Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer.
    J Clin Oncol. 2024 Jun 25:JCO2302643. doi: 10.1200/JCO.23.02643.
    PubMed     Abstract available


  32. KUSUMOTO M, Shimomura A, Shimizu C
    Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer.
    J Clin Oncol. 2024 Jun 24:JCO2302407. doi: 10.1200/JCO.23.02407.
    PubMed    


  33. CORTES J, Hurvitz SA, O'Shaughnessy J, Delaloge S, et al
    Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
    J Clin Oncol. 2024 Jun 18:JCO2302036. doi: 10.1200/JCO.23.02036.
    PubMed     Abstract available


  34. SANDOVAL JL, Franzoi MA, di Meglio A, Ferreira AR, et al
    Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort.
    J Clin Oncol. 2024 Jun 18:JCO2302099. doi: 10.1200/JCO.23.02099.
    PubMed     Abstract available


  35. SOLDATO D, Michiels S, Havas J, Di Meglio A, et al
    Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.
    J Clin Oncol. 2024 Jun 5:JCO2301959. doi: 10.1200/JCO.23.01959.
    PubMed     Abstract available


  36. CHAVEZ-MACGREGOR M, Miao J, Pusztai L, Goetz MP, et al
    Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
    J Clin Oncol. 2024 Jun 4:JCO2302344. doi: 10.1200/JCO.23.02344.
    PubMed     Abstract available


  37. BOSTANY G, Chen Y, Francisco L, Dai C, et al
    Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.
    J Clin Oncol. 2024 Jun 4:JCO2301779. doi: 10.1200/JCO.23.01779.
    PubMed     Abstract available


  38. SCHNEIDER BP, Zhao F, Ballinger TJ, Garcia SF, et al
    ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2024 Jun 3:JCO2400526. doi: 10.1200/JCO.24.00526.
    PubMed     Abstract available


  39. CHAPMAN JW, Bayani J, SenGupta S, Bartlett JMS, et al
    Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
    J Clin Oncol. 2024 Jun 2:JCO2400835. doi: 10.1200/JCO.24.00835.
    PubMed     Abstract available


  40. RECHT A
    Internal Mammary Node Irradiation Debate: Case Closed? Not Yet, and Maybe Never.
    J Clin Oncol. 2024;42:1871-1874.
    PubMed     Abstract available


  41. SORSCHER S
    Omission of Radiotherapy for Women With Low-Risk Invasive Cancers That Have a Ductal Carcinoma In Situ Component.
    J Clin Oncol. 2024;42:1998.
    PubMed    


    May 2024
  42. AZIM HA JR, Niman SM, Partridge AH, Demeestere I, et al
    Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
    J Clin Oncol. 2024 May 29:JCO2302292. doi: 10.1200/JCO.23.02292.
    PubMed     Abstract available


  43. LU YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, et al
    Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
    J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144.
    PubMed     Abstract available


  44. SANTHOSH A, Sharma A, Bakhshi S, Kumar A, et al
    Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1821-1829.
    PubMed     Abstract available


  45. FREEDMAN RA, Caswell-Jin JL, Hassett M, Somerfield MR, et al
    Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 May 20:JCO2400886. doi: 10.1200/JCO.24.00886.
    PubMed     Abstract available


  46. RAPP SR, Dressler EV, Brown WM, Wade JL 3rd, et al
    Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).
    J Clin Oncol. 2024 May 6:JCO2301100. doi: 10.1200/JCO.23.01100.
    PubMed     Abstract available


    April 2024

  47. Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Yea
    J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711.
    PubMed    


  48. BARDIA A, Krop IE, Kogawa T, Juric D, et al
    Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
    J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909.
    PubMed     Abstract available


  49. RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
    Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
    PubMed    


  50. VALENZA C, Trapani D, Loibl S, Chia SKL, et al
    Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
    J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935.
    PubMed     Abstract available


  51. MUTTER RW, Chauhan C, Goetz MP, Wright JL, et al
    Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens.
    J Clin Oncol. 2024 Apr 2:JCO2302289. doi: 10.1200/JCO.23.02289.
    PubMed    


    March 2024
  52. MARTIN M, Lim E, Chavez-MacGregor M, Bardia A, et al
    Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
    J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500.
    PubMed     Abstract available


  53. MAYER EL, Ren Y, Wagle N, Mahtani R, et al
    PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Bre
    J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940.
    PubMed     Abstract available


  54. SALTBAEK L, Bidstrup PE, Karlsen RV, Hoeg BL, et al
    Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.
    J Clin Oncol. 2024 Mar 18:JCO2301447. doi: 10.1200/JCO.23.01447.
    PubMed     Abstract available


  55. MANN GB, Rose AK, Zdenkowski N
    What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?
    J Clin Oncol. 2024 Mar 15:JCO2302729. doi: 10.1200/JCO.23.02729.
    PubMed    


  56. BURSTEIN HJ, DeMichele A, Fallowfield L, Somerfield MR, et al
    Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
    J Clin Oncol. 2024 Mar 13:JCO2400248. doi: 10.1200/JCO.24.00248.
    PubMed     Abstract available


  57. RADFORD J
    Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
    J Clin Oncol. 2024 Mar 13:JCO2302763. doi: 10.1200/JCO.23.02763.
    PubMed    


    February 2024
  58. MARS N, Kerminen S, Tamlander M, Pirinen M, et al
    Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
    J Clin Oncol. 2024 Feb 29:JCO2300295. doi: 10.1200/JCO.23.00295.
    PubMed     Abstract available


  59. BARDIA A, Rugo HS, Tolaney SM, Loirat D, et al
    Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    J Clin Oncol. 2024 Feb 29:JCO2301409. doi: 10.1200/JCO.23.01409.
    PubMed     Abstract available


  60. MAXWELL KN, Domchek SM
    Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.
    J Clin Oncol. 2024 Feb 29:JCO2400029. doi: 10.1200/JCO.24.00029.
    PubMed    



  61. Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
    J Clin Oncol. 2024 Feb 23:JCO2400317. doi: 10.1200/JCO.24.00317.
    PubMed    


  62. WORIAX HE, Thomas SM, Plichta JK, Rosenberger LH, et al
    Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
    J Clin Oncol. 2024 Feb 23:JCO2301199. doi: 10.1200/JCO.23.01199.
    PubMed     Abstract available


  63. SHAH M, Lingam H, Gao X, Gittleman H, et al
    US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.
    J Clin Oncol. 2024 Feb 21:JCO2302112. doi: 10.1200/JCO.23.02112.
    PubMed     Abstract available


  64. MCGRADY ME, Willard VW, Williams AM, Brinkman TM, et al
    Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.
    J Clin Oncol. 2024;42:707-716.
    PubMed     Abstract available


  65. CHEN JC, Elsaid MI, Handley D, Plascak JJ, et al
    Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer.
    J Clin Oncol. 2024 Feb 16:JCO2300907. doi: 10.1200/JCO.23.00907.
    PubMed     Abstract available


  66. NEPPELENBROEK SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, et al
    Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386.
    PubMed     Abstract available


  67. GEYER CE JR, Blum JL, Yothers G, Asmar L, et al
    Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
    J Clin Oncol. 2024 Feb 9:JCO2301428. doi: 10.1200/JCO.23.01428.
    PubMed     Abstract available


  68. GANZ PA, Bandos H, Spanic T, Friedman S, et al
    Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
    J Clin Oncol. 2024 Feb 1:JCO2301214. doi: 10.1200/JCO.23.01214.
    PubMed     Abstract available


    January 2024

  69. Erratum: Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2400028. doi: 10.1200/JCO.24.00028.
    PubMed    


  70. SLAMON DJ, Dieras V, Rugo HS, Harbeck N, et al
    Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2300137. doi: 10.1200/JCO.23.00137.
    PubMed     Abstract available


  71. ALAEIKHANEHSHIR S, Ajayi T, Duijnhoven FH, Poncet C, et al
    Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
    J Clin Oncol. 2024 Jan 19:JCO2202690. doi: 10.1200/JCO.22.02690.
    PubMed     Abstract available


  72. RASTOGI P, O'Shaughnessy J, Martin M, Boyle F, et al
    Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficac
    J Clin Oncol. 2024 Jan 9:JCO2301994. doi: 10.1200/JCO.23.01994.
    PubMed     Abstract available


  73. MORGANTI S, Gibson CJ, Jin Q, Santos K, et al
    Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
    J Clin Oncol. 2024 Jan 8:JCO2301071. doi: 10.1200/JCO.23.01071.
    PubMed     Abstract available


  74. BEDROSIAN I, Somerfield MR, Achatz MI, Boughey JC, et al
    Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
    J Clin Oncol. 2024 Jan 4:JCO2302225. doi: 10.1200/JCO.23.02225.
    PubMed     Abstract available


  75. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    J Clin Oncol. 2024;42:47-58.
    PubMed     Abstract available


    December 2023

  76. Erratum: Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth
    J Clin Oncol. 2023 Dec 19:JCO2302620. doi: 10.1200/JCO.23.02620.
    PubMed    


  77. TIMMINS IR, Jones ME, O'Brien KM, Adami HO, et al
    International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts.
    J Clin Oncol. 2023 Dec 11:JCO2301101. doi: 10.1200/JCO.23.01101.
    PubMed     Abstract available


  78. JAGSI R, Griffith KA, Harris EE, Wright JL, et al
    Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.
    J Clin Oncol. 2023 Dec 7:JCO2302270. doi: 10.1200/JCO.23.02270.
    PubMed     Abstract available


  79. BRAUNSTEIN LZ, Khan AJ
    Optimization of Breast Cancer Regional Nodal Management.
    J Clin Oncol. 2023 Dec 4:JCO2302121. doi: 10.1200/JCO.23.02121.
    PubMed    


    November 2023
  80. GARD CC, Tice JA, Miglioretti DL, Sprague BL, et al
    Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.
    J Clin Oncol. 2023 Nov 17:JCO2202470. doi: 10.1200/JCO.22.02470.
    PubMed     Abstract available


  81. NAOUM GE, Oladeru O, Ababneh H, Shui A, et al
    Pathological Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
    J Clin Oncol. 2023 Nov 15:JCO2301009. doi: 10.1200/JCO.23.01009.
    PubMed     Abstract available


  82. HIS M, Gunter MJ, Keski-Rahkonen P, Rinaldi S, et al
    Application of Metabolomics to Epidemiologic Studies of Breast Cancer: New Perspectives for Etiology and Prevention.
    J Clin Oncol. 2023 Nov 9:JCO2202754. doi: 10.1200/JCO.22.02754.
    PubMed     Abstract available


  83. BIDARD FC, Kiavue N, Jacot W, Bachelot T, et al
    Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
    J Clin Oncol. 2023 Nov 6:JCO2300456. doi: 10.1200/JCO.23.00456.
    PubMed     Abstract available


    October 2023
  84. YOSHITOMI Y, Shimomura A, Shimizu C
    Oral Selective Estrogen Receptor Degrader for Advanced Breast Cancer.
    J Clin Oncol. 2023 Oct 30:JCO2301656. doi: 10.1200/JCO.23.01656.
    PubMed    


  85. ESKREIS-WINKLER S, Sung JS, Dixon L, Monga N, et al
    High-Temporal/High-Spatial Resolution Breast Magnetic Resonance Imaging Improves Diagnostic Accuracy Compared With Standard Breast Magnetic Resonance Imaging in Patients With High Background Parenchymal Enhancement.
    J Clin Oncol. 2023;41:4747-4755.
    PubMed     Abstract available


  86. KROP IE, Masuda N, Mukohara T, Takahashi S, et al
    Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II
    J Clin Oncol. 2023 Oct 6:JCO2300882. doi: 10.1200/JCO.23.00882.
    PubMed     Abstract available


  87. CAO C, Ligibel JA
    Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.
    J Clin Oncol. 2023 Oct 5:JCO2301516. doi: 10.1200/JCO.23.01516.
    PubMed    


    September 2023
  88. CONTE P, Bisagni G, Piacentini F, Sarti S, et al
    Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
    J Clin Oncol. 2023 Sep 25:JCO2300790. doi: 10.1200/JCO.23.00790.
    PubMed     Abstract available


  89. IM C, Sharafeldin N, Yuan Y, Wang Z, et al
    Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.
    J Clin Oncol. 2023;41:4381-4393.
    PubMed     Abstract available



  90. Erratum: Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.
    J Clin Oncol. 2023 Sep 12:JCO2301807. doi: 10.1200/JCO.23.01807.
    PubMed    


  91. GOODWIN PJ, Chen BE, Gelmon KA, Whelan TJ, et al
    Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
    J Clin Oncol. 2023 Sep 11:JCO2300296. doi: 10.1200/JCO.23.00296.
    PubMed     Abstract available


  92. HOE HJ, Solomon BJ
    Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
    J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
    PubMed    


  93. PARKER JS, Mullins M, Cheang MCU, Leung S, et al
    Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.
    J Clin Oncol. 2023;41:4192-4199.
    PubMed     Abstract available



  94. JCO Flashback: An Intrinsic Subtype-Based Risk Prediction Model for Early-Stage Breast Cancer (2009).
    J Clin Oncol. 2023;41:4191.
    PubMed    


  95. SOLDATO D, Miller KD
    Flashback Foreword: Supervised Risk Predictor of Breast Cancer.
    J Clin Oncol. 2023;41:4189-4190.
    PubMed    


  96. SANFT T, Harrigan M, McGowan C, Cartmel B, et al
    Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.
    J Clin Oncol. 2023 Sep 1:JCO2300871. doi: 10.1200/JCO.23.00871.
    PubMed     Abstract available


    August 2023
  97. PUSZTAI L, Rozenblit M, Dubsky P, Bachelot T, et al
    De Novo Oligometastatic Breast Cancer.
    J Clin Oncol. 2023 Aug 22:JCO2300911. doi: 10.1200/JCO.23.00911.
    PubMed    


  98. BAEK SY, Noh WC, Ahn SH, Kim HA, et al
    Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
    J Clin Oncol. 2023 Aug 22:JCO2300557. doi: 10.1200/JCO.23.00557.
    PubMed     Abstract available


  99. PFEILER G, Hlauschek D, Mayer EL, Deutschmann C, et al
    Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
    J Clin Oncol. 2023 Aug 9:JCO2300126. doi: 10.1200/JCO.23.00126.
    PubMed     Abstract available


  100. WILKINSON AN, Ellison LF, Billette JM, Seely JM, et al
    Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.
    J Clin Oncol. 2023 Aug 4:JCO2300348. doi: 10.1200/JCO.23.00348.
    PubMed     Abstract available


  101. BRIGHT EE, Finkelstein LB, Nealis MS, Genung SR, et al
    A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    J Clin Oncol. 2023 Aug 2:JCO2300697. doi: 10.1200/JCO.23.00697.
    PubMed     Abstract available


    July 2023

  102. Erratum: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    J Clin Oncol. 2023 Jul 14:JCO2301370. doi: 10.1200/JCO.23.01370.
    PubMed    


  103. YU KD
    Inconsistent Data Between Distant Relapse Events and Breast Cancer-Specific Death Events in India Lidocaine Trial.
    J Clin Oncol. 2023 Jul 11:JCO2300976. doi: 10.1200/JCO.23.00976.
    PubMed    


  104. LITTON JK, Regan MM, Pusztai L, Rugo HS, et al
    Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
    J Clin Oncol. 2023 Jul 11:JCO2300435. doi: 10.1200/JCO.23.00435.
    PubMed     Abstract available


  105. PAIK S, Tang G, Shak S, Kim C, et al
    Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2023;41:3565-3575.
    PubMed     Abstract available


  106. WOLFF AC
    Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer.
    J Clin Oncol. 2023;41:3563-3564.
    PubMed    


  107. JACKSON EB, Chia SKL
    Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2023 Jul 5:JCO2300759. doi: 10.1200/JCO.23.00759.
    PubMed     Abstract available


    June 2023

  108. Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD
    J Clin Oncol. 2023 Jun 26:JCO2301239. doi: 10.1200/JCO.23.01239.
    PubMed    



  109. Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2023 Jun 26:JCO2301230. doi: 10.1200/JCO.23.01230.
    PubMed    


  110. PUSZTAI L
    Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?
    J Clin Oncol. 2023 Jun 22:JCO2300977. doi: 10.1200/JCO.23.00977.
    PubMed    


  111. TOLANEY SM, Chan A, Petrakova K, Delaloge S, et al
    AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2023 Jun 22:JCO2202746. doi: 10.1200/JCO.22.02746.
    PubMed     Abstract available


  112. LAZZERONI M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, et al
    Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
    J Clin Oncol. 2023;41:3116-3121.
    PubMed     Abstract available


  113. WOLFF AC, Somerfield MR, Dowsett M, Hammond MEH, et al
    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.
    J Clin Oncol. 2023 Jun 7:JCO2202864. doi: 10.1200/JCO.22.02864.
    PubMed     Abstract available


  114. WANG Y, Cai Q
    Could Adjuvant Radiotherapy Be Avoided for Postmenopausal Patients With Node-Positive Estrogen Receptor-Positive Breast Cancer and Favorable Recurrence Score and SET2,3 Scores?
    J Clin Oncol. 2023 Jun 1:JCO2300210. doi: 10.1200/JCO.23.00210.
    PubMed    


    May 2023
  115. DAYES IS, Metser U, Hodgson N, Parpia S, et al
    Impact of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.
    J Clin Oncol. 2023 May 26:JCO2300249. doi: 10.1200/JCO.23.00249.
    PubMed     Abstract available


  116. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available


  117. KALINSKY K, Accordino MK, Chiuzan C, Mundi PS, et al
    Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Tr
    J Clin Oncol. 2023 May 19:JCO2202392. doi: 10.1200/JCO.22.02392.
    PubMed     Abstract available


  118. BURSTEIN HJ, DeMichele A, Somerfield MR, Henry NL, et al
    Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 May 17:JCO2300638. doi: 10.1200/JCO.23.00638.
    PubMed     Abstract available



  119. Erratum: Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2023 May 10:JCO2300870. doi: 10.1200/JCO.23.00870.
    PubMed    


  120. LAWS A, Punglia RS
    Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
    J Clin Oncol. 2023 May 1:JCO2300455. doi: 10.1200/JCO.23.00455.
    PubMed     Abstract available


  121. BERG WA, Zuley ML, Chang TS, Gizienski TA, et al
    Prospective Multicenter Diagnostic Performance of Technologist-Performed Screening Breast Ultrasound After Tomosynthesis in Women With Dense Breasts (the DBTUST).
    J Clin Oncol. 2023;41:2403-2415.
    PubMed     Abstract available


    April 2023
  122. ROYCE M, Mulkey F, Osgood C, Bloomquist E, et al
    US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2300615. doi: 10.1200/JCO.23.00615.
    PubMed    


  123. VACHON CM, Scott CG, Norman AD, Khanani SA, et al
    Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer.
    J Clin Oncol. 2023 Apr 27:JCO2201153. doi: 10.1200/JCO.22.01153.
    PubMed     Abstract available


  124. IWASE T, Saji S, Iijima K, Higaki K, et al
    Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2023 Apr 20:JCO2200577. doi: 10.1200/JCO.22.00577.
    PubMed     Abstract available


  125. ESSERMAN LJ, Ali H, McKenzie T
    When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
    J Clin Oncol. 2023;41:2144-2150.
    PubMed     Abstract available


  126. MEDURI B, Baldissera A, Iotti C, Scheijmans LJEE, et al
    Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
    J Clin Oncol. 2023;41:2201-2210.
    PubMed     Abstract available


  127. VAN MACKELENBERGH MT, Loibl S, Untch M, Buyse M, et al
    Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2023 Apr 19:JCO2202241. doi: 10.1200/JCO.22.02241.
    PubMed     Abstract available


  128. ZHAO YF, Du JX, Zhu W
    A Brand New BRCA-CRisk Model Precisely Predicts the Prognosis of Patients With Breast Cancer and BRCA1/2 Mutation.
    J Clin Oncol. 2023 Apr 11:JCO2202893. doi: 10.1200/JCO.22.02893.
    PubMed    


  129. HIGGINS T, Mittendorf EA
    Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer.
    J Clin Oncol. 2023 Apr 6:JCO2300418. doi: 10.1200/JCO.23.00418.
    PubMed    


  130. BADWE RA, Parmar V, Nair N, Joshi S, et al
    Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.
    J Clin Oncol. 2023 Apr 6:JCO2201966. doi: 10.1200/JCO.22.01966.
    PubMed     Abstract available


  131. FISHER B, Bryant J, Wolmark N, Mamounas E, et al
    Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
    J Clin Oncol. 2023;41:1795-1808.
    PubMed     Abstract available


  132. LIEDTKE C, Mazouni C, Hess KR, Andre F, et al
    Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
    J Clin Oncol. 2023;41:1809-1815.
    PubMed     Abstract available


  133. HUDIS CA
    Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer.
    J Clin Oncol. 2023;41:1793-1794.
    PubMed    


  134. SPEERS CW, Symmans WF, Barlow WE, Trevarton A, et al
    Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
    J Clin Oncol. 2023;41:1841-1848.
    PubMed     Abstract available


  135. JI X, Shi KS, Mertens AC, Zhao J, et al
    Survival in Young Adults With Cancer Is Associated With Medicaid Expansion Through the Affordable Care Act.
    J Clin Oncol. 2023;41:1909-1920.
    PubMed     Abstract available


    March 2023
  136. BOUGHEY JC, Rosenkranz KM, Ballman KV, McCall L, et al
    Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
    J Clin Oncol. 2023 Mar 28:JCO2202553. doi: 10.1200/JCO.22.02553.
    PubMed     Abstract available


  137. SQUIFFLET P, Saad ED, Loibl S, van Mackelenbergh MT, et al
    Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Re
    J Clin Oncol. 2023 Mar 28:JCO2202363. doi: 10.1200/JCO.22.02363.
    PubMed     Abstract available


  138. PLICHTA JK, Thomas SM, Hayes DF, Chavez-MacGregor M, et al
    Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
    J Clin Oncol. 2023 Mar 21:JCO2202222. doi: 10.1200/JCO.22.02222.
    PubMed     Abstract available


  139. VOGEL CL, Cobleigh MA, Tripathy D, Gutheil JC, et al
    Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
    J Clin Oncol. 2023;41:1638-1645.
    PubMed     Abstract available



  140. JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002).
    J Clin Oncol. 2023;41:1637.
    PubMed    


  141. GRIGGS JJ
    Flashback Foreword: Activity of First-Line Trastuzumab.
    J Clin Oncol. 2023;41:1635-1636.
    PubMed    


  142. ERIKSSON M, Czene K, Vachon C, Conant EF, et al
    Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer.
    J Clin Oncol. 2023 Mar 17:JCO2201564. doi: 10.1200/JCO.22.01564.
    PubMed     Abstract available


  143. COBLEIGH MA, Vogel CL, Tripathy D, Robert NJ, et al
    Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
    J Clin Oncol. 2023;41:1501-1510.
    PubMed     Abstract available


  144. HARVEY JM, Clark GM, Osborne CK, Allred DC, et al
    Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.
    J Clin Oncol. 2023;41:1331-1338.
    PubMed     Abstract available


  145. GANZ PA
    Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer.
    J Clin Oncol. 2023;41:1329-1330.
    PubMed    


    February 2023
  146. HARBECK N, Nitz UA, Christgen M, Kummel S, et al
    De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    J Clin Oncol. 2023 Feb 21:JCO2201816. doi: 10.1200/JCO.22.01816.
    PubMed     Abstract available


  147. NARAYAN P, Dilawari A, Osgood C, Feng Z, et al
    US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
    J Clin Oncol. 2023 Feb 13:JCO2202447. doi: 10.1200/JCO.22.02447.
    PubMed     Abstract available


  148. YANG S, Tan M, Gao F, Xu X, et al
    Cognitive Problems in Older Breast Cancer Survivors.
    J Clin Oncol. 2023 Feb 13:JCO2202282. doi: 10.1200/JCO.22.02282.
    PubMed    


    January 2023
  149. TAGLIAMENTO M, Gennari A, Lambertini M, Salazar R, et al
    Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.
    J Clin Oncol. 2023 Jan 31:JCO2201667. doi: 10.1200/JCO.22.01667.
    PubMed     Abstract available


  150. TRAPANI D
    Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
    J Clin Oncol. 2023 Jan 30:JCO2202477. doi: 10.1200/JCO.22.02477.
    PubMed     Abstract available


  151. LEVASSEUR N, Gelmon KA
    Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care.
    J Clin Oncol. 2023 Jan 26:JCO2202863. doi: 10.1200/JCO.22.02863.
    PubMed    


  152. LOPES CARDOZO JMN, Andrulis IL, Bojesen SE, Dork T, et al
    Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
    J Clin Oncol. 2023 Jan 23:JCO2201978. doi: 10.1200/JCO.22.01978.
    PubMed     Abstract available


  153. HERSHMAN DL, Bansal A, Sullivan SD, Barlow WE, et al
    A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
    J Clin Oncol. 2023;41:590-598.
    PubMed     Abstract available


  154. KONSTANTINOPOULOS PA, Lee EK, Xiong N, Krasner C, et al
    A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:599-608.
    PubMed     Abstract available


  155. MOY B, Rumble RB, Carey LA
    Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Jan 10:JCO2202807. doi: 10.1200/JCO.22.02807.
    PubMed     Abstract available


  156. YADAV S, Boddicker NJ, Na J, Polley EC, et al
    Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
    J Clin Oncol. 2023 Jan 9:JCO2201239. doi: 10.1200/JCO.22.01239.
    PubMed     Abstract available


  157. SG N, Gogia A
    Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2023 Jan 6:JCO2202113. doi: 10.1200/JCO.22.02113.
    PubMed    


  158. NATTINGER AB, Bickell NA, Schymura MJ, Laud P, et al
    Centralization of Initial Care and Improved Survival of Poor Patients With Breast Cancer.
    J Clin Oncol. 2023 Jan 5:JCO2202012. doi: 10.1200/JCO.22.02012.
    PubMed     Abstract available


  159. SJOSTROM M, Fyles A, Liu FF, McCready D, et al
    Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2023 Jan 4:JCO2200655. doi: 10.1200/JCO.22.00655.
    PubMed     Abstract available


    December 2022
  160. NAOUM GE, Taghian AG
    Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right?
    J Clin Oncol. 2022 Dec 20:JCO2202171. doi: 10.1200/JCO.22.02171.
    PubMed    


  161. NISHIHARA R, Shimomura A, Shimizu C
    Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor.
    J Clin Oncol. 2022;40:4280-4281.
    PubMed    


  162. CONNOLLY RM, Miller KD
    Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
    J Clin Oncol. 2022 Dec 15:JCO2202319. doi: 10.1200/JCO.22.02319.
    PubMed    


  163. PAGANI O, Walley BA, Fleming GF, Colleoni M, et al
    Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
    J Clin Oncol. 2022 Dec 15:JCO2201064. doi: 10.1200/JCO.22.01064.
    PubMed     Abstract available


  164. FRANCIS PA, Fleming GF, Lang I, Ciruelos EM, et al
    Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    J Clin Oncol. 2022 Dec 9:JCO2201065. doi: 10.1200/JCO.22.01065.
    PubMed     Abstract available


  165. BEHROOZIAN T, Milton L, Karam I, Zhang L, et al
    Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2022 Dec 9:JCO2201873. doi: 10.1200/JCO.22.01873.
    PubMed     Abstract available


  166. SUN J, Chu F, Pan J, Zhang Y, et al
    BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
    J Clin Oncol. 2022 Dec 8:JCO2200833. doi: 10.1200/JCO.22.00833.
    PubMed     Abstract available


  167. SEDRAK MS, Sun CL, Ji J, Cohen HJ, et al
    Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
    J Clin Oncol. 2022 Dec 1:JCO2201440. doi: 10.1200/JCO.22.01440.
    PubMed     Abstract available


  168. JAYASEKERA J, Zhao A, Schechter C, Lowry K, et al
    Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Dec 1:JCO2201342. doi: 10.1200/JCO.22.01342.
    PubMed     Abstract available


    November 2022
  169. SANTA-MARIA CA, Wolff AC
    Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets.
    J Clin Oncol. 2022 Nov 29:JCO2202217. doi: 10.1200/JCO.22.02217.
    PubMed    


  170. BARTELS SAL, Donker M, Poncet C, Sauve N, et al
    Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
    J Clin Oncol. 2022 Nov 16:JCO2201565. doi: 10.1200/JCO.22.01565.
    PubMed     Abstract available


  171. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
    FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
    J Clin Oncol. 2022;40:3750-3761.
    PubMed     Abstract available


  172. RUGO HS, Im SA, Cardoso F, Cortes J, et al
    Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
    J Clin Oncol. 2022 Nov 4:JCO2102937. doi: 10.1200/JCO.21.02937.
    PubMed     Abstract available


  173. MORAN MS, Ho AY
    Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
    J Clin Oncol. 2022 Nov 4:JCO2201751. doi: 10.1200/JCO.22.01751.
    PubMed     Abstract available


  174. MCCAW ZR, Ludmir EB, Wei LJ
    Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    J Clin Oncol. 2022 Nov 3:JCO2201759. doi: 10.1200/JCO.22.01759.
    PubMed    


  175. AKECHI T, Yamaguchi T, Uchida M, Imai F, et al
    Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
    J Clin Oncol. 2022 Nov 2:JCO2200699. doi: 10.1200/JCO.22.00699.
    PubMed     Abstract available


  176. HINDIE E, Groheux D
    Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
    J Clin Oncol. 2022;40:3669-3670.
    PubMed    


  177. GAIL MH, Jatoi I
    Tools for Contralateral Prophylactic Mastectomy Decision Making.
    J Clin Oncol. 2022;40:3653-3659.
    PubMed     Abstract available


    October 2022
  178. EVRON E, Ben-David MA, Kaidar-Person O, Corn BW, et al
    Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609.
    PubMed    


  179. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    PubMed     Abstract available


  180. SANCHEZ KG, Nangia JR, Schiff R, Rimawi MF, et al
    Elacestrant and the Promise of Oral SERDs.
    J Clin Oncol. 2022;40:3227-3229.
    PubMed    


    September 2022
  181. CARROLL JE, Nakamura ZM, Small BJ, Zhou X, et al
    Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
    J Clin Oncol. 2022 Sep 30:JCO2200406. doi: 10.1200/JCO.22.00406.
    PubMed     Abstract available


  182. JI J, Sun CL, Cohen HJ, Synold T, et al
    Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
    J Clin Oncol. 2022 Sep 20:JCO2201217. doi: 10.1200/JCO.22.01217.
    PubMed     Abstract available


  183. LV M, Luo X, Chen Y
    Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology.
    J Clin Oncol. 2022 Sep 19:JCO2201061. doi: 10.1200/JCO.22.01061.
    PubMed    


  184. WHEELER SB, Rotter J, Gogate A, Reeder-Hayes KE, et al
    Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Sep 2:JCO2102473. doi: 10.1200/JCO.21.02473.
    PubMed     Abstract available


    August 2022
  185. MANKOFF DA, Clark AS, Edmonds CE, O'Brien SR, et al
    16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer.
    J Clin Oncol. 2022 Aug 30:JCO2201055. doi: 10.1200/JCO.22.01055.
    PubMed    


  186. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201002. doi: 10.1200/JCO.22.01002.
    PubMed     Abstract available


  187. DAVIDSON NE
    In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201465. doi: 10.1200/JCO.22.01465.
    PubMed    


  188. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
    Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.
    J Clin Oncol. 2022 Aug 5:JCO2200451. doi: 10.1200/JCO.22.00451.
    PubMed     Abstract available


  189. MOY B, Rumble RB, Carey LA
    Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Aug 4:JCO2201533. doi: 10.1200/JCO.22.01533.
    PubMed     Abstract available


    July 2022
  190. JOHANSSON A, Dar H, van 't Veer LJ, Tobin NP, et al
    Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    J Clin Oncol. 2022 Jul 21:JCO2102844. doi: 10.1200/JCO.21.02844.
    PubMed     Abstract available


  191. RUGO HS, Umanzor GA, Barrios FJ, Vasallo RH, et al
    Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    J Clin Oncol. 2022 Jul 20:JCO2102953. doi: 10.1200/JCO.21.02953.
    PubMed     Abstract available


  192. ULAS KAHYA B, Sutcuoglu O, Yazici O, Ozdemir N, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jul 12:JCO2200404. doi: 10.1200/JCO.22.00404.
    PubMed    


  193. SORAN A, Aytac O, Ozbas S
    Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
    J Clin Oncol. 2022 Jul 12:JCO2200802. doi: 10.1200/JCO.22.00802.
    PubMed    


  194. LU Y, Meng D, Hui B, Yuan W, et al
    The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
    J Clin Oncol. 2022 Jul 5:JCO2200931. doi: 10.1200/JCO.22.00931.
    PubMed    


    June 2022
  195. COBAIN EF, Hayes DF
    Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 29:JCO2200702. doi: 10.1200/JCO.22.00702.
    PubMed    


  196. HUOBER J, Barrios CH, Niikura N, Jarzab M, et al
    Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
    J Clin Oncol. 2022 Jun 28:JCO2102772. doi: 10.1200/JCO.21.02772.
    PubMed     Abstract available


  197. HENRY NL, Somerfield MR, Dayao Z, Elias A, et al
    Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Jun 27:JCO2201063. doi: 10.1200/JCO.22.01063.
    PubMed     Abstract available


  198. CHEN YJ, Yeh MH, Wei JC
    Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200416. doi: 10.1200/JCO.22.00416.
    PubMed    


  199. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    


  200. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available


  201. REDING KW, Cheng RK, Barac A, Vasbinder A, et al
    Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
    J Clin Oncol. 2022 Jun 10:JCO2200111. doi: 10.1200/JCO.22.00111.
    PubMed    


  202. MITTENDORF EA, King TA, Tolaney SM
    Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.
    PubMed    


  203. CESCON DW, Kalinsky K, DeMichele AM
    Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
    J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.
    PubMed    


  204. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
    Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
    PubMed     Abstract available


  205. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available


  206. ZACHARAKIS N, Huq LM, Seitter SJ, Kim SP, et al
    Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
    J Clin Oncol. 2022;40:1741-1754.
    PubMed     Abstract available


    May 2022
  207. GIORDANO SH, Franzoi MAB, Temin S, Anders CK, et al
    Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200519. doi: 10.1200/JCO.22.00519.
    PubMed     Abstract available


  208. RAMAKRISHNA N, Anders CK, Lin NU, Morikawa A, et al
    Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200520. doi: 10.1200/JCO.22.00520.
    PubMed     Abstract available


  209. BACHELOT T, Cottu P, Chabaud S, Dalenc F, et al
    Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    J Clin Oncol. 2022 May 23:JCO2102179. doi: 10.1200/JCO.21.02179.
    PubMed     Abstract available


  210. VAN GEEL JJL, Boers J, Elias SG, Glaudemans AWJM, et al
    Clinical Validity of 16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
    J Clin Oncol. 2022 May 18:JCO2200400. doi: 10.1200/JCO.22.00400.
    PubMed     Abstract available


  211. BIDARD FC, Kaklamani VG, Neven P, Streich G, et al
    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
    J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
    PubMed     Abstract available


  212. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    


  213. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    


  214. DAMODARAN S, Zhao F, Deming DA, Mitchell EP, et al
    Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    J Clin Oncol. 2022;40:1552-1561.
    PubMed     Abstract available


  215. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available


  216. SINGLETON AC, Raeside R, Hyun KK, Partridge SR, et al
    Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses.
    J Clin Oncol. 2022 May 2:JCO2101171. doi: 10.1200/JCO.21.01171.
    PubMed     Abstract available


    April 2022
  217. JIN Z, Zhang S, Zhang L, Chen Q, et al
    Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102908. doi: 10.1200/JCO.21.02908.
    PubMed    


  218. ERIKSSON M, Conant EF, Kontos D, Hall P, et al
    Risk Assessment in Population-Based Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102827. doi: 10.1200/JCO.21.02827.
    PubMed    


  219. DI MEGLIO A, Havas J, Gbenou AS, Martin E, et al
    Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
    J Clin Oncol. 2022 Apr 21:JCO2100277. doi: 10.1200/JCO.21.00277.
    PubMed     Abstract available


  220. VLIEK SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, et al
    Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
    J Clin Oncol. 2022 Apr 20:JCO2100311. doi: 10.1200/JCO.21.00311.
    PubMed     Abstract available


  221. LOPES CARDOZO JMN, Drukker CA, Rutgers EJT, Schmidt MK, et al
    Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    J Clin Oncol. 2022;40:1335-1345.
    PubMed     Abstract available


  222. BEAVIS PA, Derrick EB, Loi S
    Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.
    J Clin Oncol. 2022 Apr 19:JCO2200284. doi: 10.1200/JCO.22.00284.
    PubMed    


  223. BRAUER ER, Ganz PA
    Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice.
    J Clin Oncol. 2022 Apr 19:JCO2200174. doi: 10.1200/JCO.22.00174.
    PubMed    


  224. ANDRE F, Ismaila N, Allison KH, Barlow WE, et al
    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Apr 19:JCO2200069. doi: 10.1200/JCO.22.00069.
    PubMed     Abstract available


  225. ASAZUMA K, Shimomura A, Shimizu C
    Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200135. doi: 10.1200/JCO.22.00135.
    PubMed    


  226. KORDE LA, Somerfield MR, Hershman DL
    Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
    PubMed     Abstract available


  227. DOWSETT M
    Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Apr 12:JCO2200214. doi: 10.1200/JCO.22.00214.
    PubMed    


  228. NITZ UA, Gluz O, Kummel S, Christgen M, et al
    Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    J Clin Oncol. 2022 Apr 11:JCO2102759. doi: 10.1200/JCO.21.02759.
    PubMed     Abstract available


  229. THORSEN LBJ, Overgaard J, Matthiessen LW, Berg M, et al
    Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study.
    J Clin Oncol. 2022 Apr 8:JCO2200044. doi: 10.1200/JCO.22.00044.
    PubMed     Abstract available


  230. GREENLEE H, Iribarren C, Rana JS, Cheng R, et al
    Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Apr 6:JCO2101736. doi: 10.1200/JCO.21.01736.
    PubMed     Abstract available


    March 2022
  231. NOZAWA K, Hattori M, Yoshimura A, Iwata H, et al
    Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
    J Clin Oncol. 2022 Mar 31:JCO2200153. doi: 10.1200/JCO.22.00153.
    PubMed    


  232. DE JONG VMT, Wang Y, Ter Hoeve ND, Opdam M, et al
    Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536.
    PubMed     Abstract available


  233. QIN B, Kim K, Goldman N, Rundle AG, et al
    Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors.
    J Clin Oncol. 2022 Mar 25:JCO2102973. doi: 10.1200/JCO.21.02973.
    PubMed     Abstract available


  234. VAZ-LUIS I, Di Meglio A, Havas J, El-Mouhebb M, et al
    Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
    J Clin Oncol. 2022 Mar 15:JCO2101958. doi: 10.1200/JCO.21.01958.
    PubMed     Abstract available


  235. SALERNO EA, Culakova E, Heckler CE, Janelsins MC, et al
    Reply to S. Ning et al.
    J Clin Oncol. 2022;40:916-918.
    PubMed    


  236. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available


  237. JATOI I
    Ductal Carcinoma In Situ and Breast Cancer Overdiagnosis.
    J Clin Oncol. 2022 Mar 4:JCO2102802. doi: 10.1200/JCO.21.02802.
    PubMed    


  238. GRIMM LJ, Plichta JK, Hwang ES
    More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk.
    J Clin Oncol. 2022 Mar 4:JCO2102733. doi: 10.1200/JCO.21.02733.
    PubMed    


  239. THOMAS A, Parsons HA, Smith KL
    Late Recurrence Following Early Breast Cancer.
    J Clin Oncol. 2022 Mar 3:JCO2200167. doi: 10.1200/JCO.22.00167.
    PubMed     Abstract available


    February 2022
  240. JAHAN N, Cathcart-Rake EJ, Ruddy KJ
    Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
    J Clin Oncol. 2022 Feb 28:JCO2200049. doi: 10.1200/JCO.22.00049.
    PubMed     Abstract available


  241. HICKS D, O'Regan RM
    Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
    J Clin Oncol. 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
    PubMed     Abstract available


  242. KEMP EB, Geerse OP, Knowles R, Woodman R, et al
    Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis.
    J Clin Oncol. 2022 Feb 16:JCO2102015. doi: 10.1200/JCO.21.02015.
    PubMed     Abstract available


  243. PEDERSEN RN, Mellemkjaer L, Ejlertsen B, Norgaard M, et al
    Mortality After Late Breast Cancer Recurrence in Denmark.
    J Clin Oncol. 2022 Feb 16:JCO2102062. doi: 10.1200/JCO.21.02062.
    PubMed     Abstract available


  244. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available


  245. ANDERSON DN, Port ER
    Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.
    J Clin Oncol. 2022 Feb 4:JCO2102706. doi: 10.1200/JCO.21.02706.
    PubMed     Abstract available


  246. PARAMANANDAM VS, Dylke E, Clark GM, Daptardar AA, et al
    Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
    J Clin Oncol. 2022 Feb 2:JCO2102567. doi: 10.1200/JCO.21.02567.
    PubMed     Abstract available


  247. PFOB A, Sidey-Gibbons C, Rauch G, Thomas B, et al
    Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    J Clin Oncol. 2022 Feb 2:JCO2102439. doi: 10.1200/JCO.21.02439.
    PubMed     Abstract available


  248. CARLOS RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, et al
    Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.
    J Clin Oncol. 2022 Feb 2:JCO2102004. doi: 10.1200/JCO.21.02004.
    PubMed    


  249. BARTON DL, Pugh SL, Ganz PA, Plaxe SC, et al
    Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
    J Clin Oncol. 2022;40:324-334.
    PubMed     Abstract available


    January 2022
  250. ROYCE M, Osgood C, Mulkey F, Bloomquist E, et al
    FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    J Clin Oncol. 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
    PubMed     Abstract available


  251. RAFN BS, Christensen J, Larsen A, Bloomquist K, et al
    Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2022 Jan 25:JCO2101681. doi: 10.1200/JCO.21.01681.
    PubMed     Abstract available


  252. DI MEGLIO A, Havas J, Soldato D, Presti D, et al
    Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
    J Clin Oncol. 2022 Jan 21:JCO2101252. doi: 10.1200/JCO.21.01252.
    PubMed     Abstract available


  253. NING S, Qiao K, Pan L
    Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073.
    PubMed    


  254. WRIGHT JL, Rahbar H, Obeng-Gyasi S, Carlos R, et al
    Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
    J Clin Oncol. 2022;40:225-230.
    PubMed    


  255. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
    CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
    J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
    PubMed     Abstract available


  256. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
    PubMed     Abstract available


  257. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
    Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
    PubMed     Abstract available


  258. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
    Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
    J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
    PubMed     Abstract available


  259. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
    PubMed     Abstract available


  260. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
    Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
    J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
    PubMed     Abstract available


    December 2021
  261. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
    BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
    PubMed     Abstract available


  262. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
    Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
    PubMed     Abstract available


  263. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
    Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    J Clin Oncol. 2021;39:3918-3926.
    PubMed     Abstract available


  264. GIORDANO SH, Freedman RA, Somerfield MR
    Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
    PubMed     Abstract available


  265. GNANT M, Dueck AC, Frantal S, Martin M, et al
    Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
    PubMed     Abstract available


    November 2021
  266. YALA A, Mikhael PG, Strand F, Lin G, et al
    Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
    J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
    PubMed     Abstract available


  267. WARREN LEG, Bellon JR
    Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
    J Clin Oncol. 2021;39:3535-3540.
    PubMed     Abstract available


  268. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
    Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
    J Clin Oncol. 2021;39:3574-3582.
    PubMed     Abstract available


    October 2021
  269. BORGES VF
    Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
    J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
    PubMed     Abstract available


  270. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
    PubMed     Abstract available


  271. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
    A Validated Risk Prediction Model for Breast Cancer in US Black Women.
    J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
    PubMed     Abstract available


    September 2021
  272. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
    Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
    PubMed     Abstract available


  273. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
    Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
    J Clin Oncol. 2021;39:2893-2902.
    PubMed     Abstract available


    July 2021
  274. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
    Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
    J Clin Oncol. 2021;39:2367-2374.
    PubMed     Abstract available


    June 2021
  275. TURAN V, Lambertini M, Lee DY, Wang E, et al
    Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
    J Clin Oncol. 2021;39:2016-2024.
    PubMed     Abstract available


  276. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
    Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
    J Clin Oncol. 2021;39:1899-1908.
    PubMed     Abstract available


    May 2021
  277. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
    Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
    J Clin Oncol. 2021;39:1458-1467.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.